This company has been marked as potentially delisted and may not be actively trading. Neuralstem (CUR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CUR vs. CLDI, NKGN, SRNE, SQZ, GNCAQ, GNCA, ELOX, PRME, PLX, and IKTShould you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Calidi Biotherapeutics (CLDI), NKGen Biotech (NKGN), Sorrento Therapeutics (SRNE), SQZ Biotechnologies (SQZ), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), Protalix BioTherapeutics (PLX), and Inhibikase Therapeutics (IKT). These companies are all part of the "medical" sector. Neuralstem vs. Its Competitors Calidi Biotherapeutics NKGen Biotech Sorrento Therapeutics SQZ Biotechnologies Genocea Biosciences Genocea Biosciences Eloxx Pharmaceuticals Prime Medicine Protalix BioTherapeutics Inhibikase Therapeutics Neuralstem (NASDAQ:CUR) and Calidi Biotherapeutics (NYSEAMERICAN:CLDI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Do institutionals and insiders hold more shares of CUR or CLDI? 38.3% of Neuralstem shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 5.4% of Neuralstem shares are held by insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, CUR or CLDI? Neuralstem has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Does the media refer more to CUR or CLDI? In the previous week, Neuralstem's average media sentiment score of 0.00 equaled Calidi Biotherapeutics'average media sentiment score. Company Overall Sentiment Neuralstem Neutral Calidi Biotherapeutics Neutral Is CUR or CLDI more profitable? Calidi Biotherapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Neuralstem's return on equity of -170.51% beat Calidi Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neuralstem-39,417.64% -170.51% -110.16% Calidi Biotherapeutics N/A -5,152.88%-175.92% Which has better earnings and valuation, CUR or CLDI? Neuralstem has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuralstem$260K16.15-$4.93MN/AN/ACalidi Biotherapeutics$50K111.82-$22.14MN/AN/A SummaryNeuralstem beats Calidi Biotherapeutics on 6 of the 9 factors compared between the two stocks. Get Neuralstem News Delivered to You Automatically Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUR vs. The Competition Export to ExcelMetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.20M$351.16M$6.05B$10.30BDividend YieldN/AN/A5.73%4.82%P/E RatioN/AN/A85.3127.10Price / Sales16.15489.32601.46133.29Price / CashN/A22.4425.7730.18Price / Book0.303.8012.676.69Net Income-$4.93M-$133.30M$3.32B$276.55M Neuralstem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CURNeuralstemN/A$2.00-4.8%N/A-41.3%$4.20M$260K0.006High Trading VolumeCLDICalidi BiotherapeuticsN/A$1.63+7.2%N/AN/A$5.58MN/A0.0038NKGNNKGen Biotech0.1324 of 5 stars$0.11flatN/A-99.3%$4.94MN/A-0.02N/ASRNESorrento Therapeutics0.8738 of 5 stars$0.00flatN/A+71.4%$1.93M$60.32M0.00800High Trading VolumeSQZSQZ BiotechnologiesN/A$0.03flatN/A+10.9%$826K$18.16M-0.011,620Gap UpGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ELOXEloxx PharmaceuticalsN/A$0.00flatN/AN/A$0.00N/A0.0030PRMEPrime Medicine3.4834 of 5 stars$5.59+0.9%$8.92+59.5%+56.0%$752.27M$4.96M-2.73234Gap UpPLXProtalix BioTherapeutics1.8778 of 5 stars$2.36+6.3%$15.00+535.6%+118.5%$177.01M$61.95M-18.15200Positive NewsIKTInhibikase Therapeutics1.2653 of 5 stars$1.61-0.6%$6.50+303.7%+9.5%$119.97MN/A-0.606 Related Companies and Tools Related Companies CLDI Alternatives NKGN Alternatives SRNE Alternatives SQZ Alternatives GNCAQ Alternatives GNCA Alternatives ELOX Alternatives PRME Alternatives PLX Alternatives IKT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUR) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuralstem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
